Clinical trialEPhase 1Completed
Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer
Neoadjuvant FOLFIRINOX and Chemoradiation Followed by Definitive Surgery and Postoperative Gemcitabine for Patients with Borderline Resectable Pancreatic Adenocarcinoma: an Intergroup Single-Arm Pilot Study
- Outcome
- Finished, no results posted
- Phase
- EPhase 1
- Status
- Completed
- Study type
- Interventional
- Start
- 29 May 2013
- Expected end
- 15 June 2018
- Enrollment
- 23 participants
- Sites
- 14
- Primary outcomes
- Accrual rate, calculated by total number of patients accrued divided by number of months from the date the study is opened at the fifth site to the evaluation date; Rate of treatment-related toxicity during preoperative therapy assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4; Rate of treatment delay (greater than 4 weeks) during preoperative therapy; Completion rate of all preoperative and operative therapy
- Sponsor
- Other
- Results posted
- No
- Last update
- 13 January 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try